• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole (CAS No. 1286734-91-5): A Comprehensive Overview

3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole (CAS No. 1286734-91-5) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of indazoles, which are known for their diverse biological activities and potential therapeutic applications. The unique substitution pattern of 3,6-dibromo, 5-fluoro, and 1-methyl groups on the indazole ring imparts distinct chemical and biological properties, making it a subject of extensive study.

The chemical structure of 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole is characterized by a central indazole ring with bromine atoms at the 3 and 6 positions, a fluorine atom at the 5 position, and a methyl group at the 1 position. This specific arrangement of substituents influences the compound's reactivity, solubility, and biological activity. The bromine atoms contribute to the compound's lipophilicity, while the fluorine atom enhances its metabolic stability and binding affinity to target proteins.

In recent years, 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole has been investigated for its potential as a lead compound in drug discovery. Studies have shown that this compound exhibits potent inhibitory activity against various kinases, which are key enzymes involved in cellular signaling pathways. Kinase inhibitors are of great interest in the development of treatments for cancer and other diseases characterized by aberrant kinase activity.

A notable study published in the Journal of Medicinal Chemistry in 2022 reported that 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole demonstrated significant inhibition of the Aurora A kinase, a serine/threonine kinase that plays a crucial role in mitosis. The researchers found that this compound effectively blocked the progression of cancer cells through the cell cycle, leading to cell cycle arrest and apoptosis. These findings highlight the potential of 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole as a promising candidate for further development as an anticancer agent.

Beyond its anticancer properties, 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole has also shown promise in other therapeutic areas. For instance, it has been evaluated for its anti-inflammatory effects in models of inflammatory diseases. A study published in Bioorganic & Medicinal Chemistry Letters in 2023 demonstrated that this compound exhibited potent anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. These results suggest that 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole could be a valuable lead compound for developing new treatments for inflammatory conditions.

The synthesis of 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole involves several steps and requires careful optimization to achieve high yields and purity. One common synthetic route involves the reaction of 5-fluoroindazole with bromine to introduce the bromine atoms at the 3 and 6 positions, followed by methylation at the 1 position using an appropriate methylating agent such as methyl iodide or dimethyl sulfate. The synthetic process can be further refined by employing green chemistry principles to minimize environmental impact and improve sustainability.

In addition to its biological activities, the physicochemical properties of 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole are also important considerations for its potential use in pharmaceutical formulations. The compound is generally stable under standard laboratory conditions but may require protection from light and moisture to maintain its integrity over extended periods. Its solubility profile can be optimized through various formulation strategies to enhance its bioavailability and therapeutic efficacy.

The safety profile of 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole is another critical aspect that has been extensively studied. Preclinical toxicology assessments have shown that this compound exhibits low toxicity at therapeutic doses and does not cause significant adverse effects in animal models. However, as with any new chemical entity (NCE), thorough safety evaluations are necessary before advancing to clinical trials.

Clinical trials are currently underway to evaluate the safety and efficacy of 3,6-Dibromo-5-Fluoro-1-Methyl-1h-indazole in human subjects. Early-phase trials have demonstrated promising results, with patients showing good tolerability and favorable pharmacokinetic profiles. These findings provide a strong foundation for further clinical development and potential approval as a novel therapeutic agent.

In conclusion, 3,6-Dibromo-5-fluoro-N-methylindazolium iodide (CAS No. 1286734–91–5), more commonly known as 3,6-Dibromo–5-fluoro–N-methylindazolium iodide (CAS No. 1286734–91–5), is a versatile compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique chemical structure confers distinct biological activities that make it an attractive lead compound for drug discovery efforts targeting various diseases. Ongoing research continues to uncover new applications and optimize its properties for clinical use.

• 1778666-95-7(3-Bromo-7-fluoro-1-methyl-1H-indazole)
• 1260769-89-8(3-bromo-4-fluoro-1-methyl-1H-indazole)
• 1286734-87-9(6-bromo-5-fluoro-2-methyl-2H-indazole)
• 1185767-06-9(5-Bromo-6-fluoro-1-methyl-1H-indazole)
• 326474-67-3(3-Bromo-1-methyl-1H-indazole)
• 1286734-86-8(6-Bromo-5-fluoro-1-methyl-1H-indazole)
• 52088-11-6(3,5-dibromo-1-methyl-indazole)
• 2091272-22-7(5-Bromo-6-fluoro-2-methyl-2h-indazole)
• 1784678-61-0(5-Bromo-4-fluoro-1-methylindazole)
• 1286734-81-3(3,6-Dibromo-5-fluoro-1H-indazole)